GoldenGolden
Advanced Search
Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

A biopharmaceutical company developing and commercializing peptide therapeutics to treat rare genetic disorders of obesity

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that is committed to revolutionalizing the care for patients that are living with rare genetic diseases of obesity. It is a company that specializes in developing molecule therapies targeting metabolic pathways for treating rare genetic diseases of obesity, diabetes and gastrointestinal functional disorders.

It focuses on the melanocortin-4 receptor (MC4R) pathway, which is saddled with the responsibility of regulating weight and hunger. By targeting the MC4R pathway, it aims to develop therapeutics for rare genetic diseases of obesity, including Proopiomelanocortin (POMC) Deficiency Obesity, Leptin Receptor (LEPR) Deficiency Obesity, Bardet-Biedl Syndrome (BBS), Alström Syndrome, POMC or LEPR Heterozygous Deficiency Obesity, Smith-Magenis Syndrome, SRC1 Deficiency Obesity, MC4R Deficiency Obesity, and SH2B1 Deficiency Obesity.

The company is leveraging the Rhythm Engine that comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program to improve the understanding, diagnosis and potentially the treatment of these disorders.

Timeline

November 27, 2020
Rhythm Pharmaceuticals announces FDA Approval of IMCIVREETM (setmelanotide) as first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency.

Funding rounds

People

Name
Role
LinkedIn

Sea-Jay Van der Ploeg

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
September 3, 2021
FierceBiotech
A series of chief medical officers (CMOs) have hit the exits over the past month, with biotechs such as Black Diamond Therapeutics, Replimune and Avidity Biosciences all disclosing departures in recent weeks. Rhythm Pharmaceuticals joined the club on Thursday--but unlike others it had a successor in place and ready to take on the job.
PANTHERx Rare Pharmacy
June 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- PANTHERx® Rare Pharmacy announced today that it was selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for...
BioSpace
November 27, 2020
BioSpace
-- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approval supports company's approach to address rare genetic diseases of obesity associated with an impaired MC4 receptor pathway -- -- People living with these rare genetic diseases of obesity struggle with insatiable hunger and excessive weight gain beginning at a young age --

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.